Medicines Optimisation

MMS® can provide tailored medicines optimisation programmes that support clinicians to provide improved healthcare for their patients. We can work alongside you to provide improved patient outcomes as well as offer significant savings for you and the NHS.

Our range of therapy optimisation programmes can be delivered with flexible models in both delivery and funding. These can include part or full sponsorship, in which case clinical reviews may be implemented with no cost implications to your GP Practice, CCG or Federation.

We can implement a fully trained clinical pharmacist to work with patients face to face or manage your medicines optimisation remotely. Our pharmacist can highlight changes that may need to be made and work to provide a solution that is clinically appropriate as well as cost effective.

QIPP Initiatives

Medicines Optimisation Programmes

Popular MMS® Programmes 

MMS® can provide a series of Therapy Optimisation Programmes that can maximise QIPP potential. These programmes are designed to optimise patient care whist releasing budgetary savings in line with national QIPP challenges.

Our range of therapy optimisation programmes can be offered with flexible models in both delivery and funding. These include part or full sponsorship, in which case clinical reviews may be implemented with no cost implications to your GP Practice, CCG or GP Federation.

An ‘invest to save’ model including options for risk share would typically deliver in excess of a five-fold return on investment. On average our suite of optimisation programmes generate a deliverable saving projection of £500,000 per 100,000 population.

Our programmes are highly customisable and can be tailored to suit your requirements. Please contact MMS® for further information and to speak to a member of our senior clinical team.

  • Dermatology

    Optimise emollient usage and review
    Ensure cost effective prescribing of emollients
    Reduce flare up related GP and Hospital appointments

  • Oral Nutritional Supplements

    Ensure appropriate prescribing in accordance with local pathways
    Incorporate care home reviews and ONS/MUST training support
    Maximise prescribing efficiencies in management of malnutrition

  • Oral Contraceptives

    To improve adherence to national UKMEC guidance and local prescribing formulary
    Optimise prescribing efficiencies
    Reduce likelihood or drug related adverse effects

  • Type II Diabetes

    Optimise therapy to achieve optimum glycaemic control in Type II Diabetes
    Review therapy in like with NICE guidance NG28
    Maximise QIPP and QOF outcomes

  • Asthma & COPD

    Review and optimise prescribing in line with updated guidance
    Reduce fluticasone burden and associated risks
    Optimise therapeutic management of Asthma and COPD

  • Care Home Support

    Polypharmacy review - STOPP/START
    Reduce wastage of medicines
    Reduce risk and unnecessary hospital admissions

  • Blood Glucose Testing

    Review and rationalise SMBG in Type II Diabetes
    Facilitate transition to formulary choice test strips
    Appropriate and cost effective prescribing

  • Atrial Fibrillation & Stroke Prevention

    Risk stratify and identify patients at risk of nvAF related stroke
    Optimise therapeutic management to reduce incidence of avoidable strokes
    Review to highlight QIPP opportunities within DOAC prescribing

  • Opioid Pain Relief

    Review prescribing in line with CQC and NHS England recommendations
    Review prescribing in line with the WHO Pain Ladder
    Review palliative care QOF indicators maximising outcomes for patients and the practice

  • Mental Health

    Incorporating Alzheimer's, Parkinson's and Schizophrenia
    Review for appropriate therapeutic monitoring and discharge reconcilliation
    Optimise prescribing efficiencies by prescribing with the lowest acquisition cost

MMS® have designed over 20 programmes to support NHS QIPP and medicines optimisation priorities
across a broad range of therapy areas & conditions. 

Key features & benefits include;

  • Optimise therapeutic management of patients

  • Promote alignment to national & local guidance

  • Maximise opportunities to reduce cost and medicines waste

  • Reduce medicines related adverse effects and admissions

Case Example: Model 1 QIPP Programme

MMS® Worked in collaboration with commissioning groups and pharma industry to meet challenges and provide significant outcomes across a CCG in the North East of England.

Screen Shot 2019-01-29 at 12.01.12

Please contact MMS for more information on our Medicines Optimisation Programmes or to speak to one of our Senior Clinical Team

Commissioning for quality

MMS® can provide skilled clinical pharmacists to undertake patient centred clinical review projects to improve patient health outcomes in line with CCG objectives and NHS Right Care strategies.
MMS® have experience in delivering in the following areas:

  • Care Home Reviews
  • Stroke Prevention
  • Domiciliary and Frailty Reviews
  • Reducing risk of hospital admission / Virtual Clinics
  • Embedding GP Practice Pharmacists

MMS Frail & Elderly Prescribing reviews – Maximising Quality Prescribing

Polypharmacy within the frail & elderly is an emerging problem and is associated with increased risks:

  • Patients on 10 or more medicines are over 3 times more likely to be admitted to hospital
  • Between 30-50% of prescribed medicines are not taken as recommended
  • Adverse Drug Reactions (ADRs) account for 6.5% of hospital admissions, of which 70% are avoidable
  • At least 6% of emergency admissions are caused by medicines

Department of Health & Social Care research has estimated that primary care medication errors leading to hospital admissions cause 627 deaths and cost the NHS £83.7m a year. in total across the NHS it is estimated that medication errors caused 712 deaths a year, costing £98.5m.

MMS have developed service models to support NHS organisations to review the most vulnerable and improve outcomes for the frail and care home populations.

If you would like more information on services that can help to improve prescribing quality and reduce the risk of admissions,
contact MMS to speak to one of our Clinical Team.